Federated Hermes
DSGN icon

Federated Hermes’s Design Therapeutics DSGN Stock Holding History

Federated Hermes’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,988
Closed -$16.1K – 2106
2024
Q3 		$16.1K Sell
2,988
-1,212
-29% -$5.7K ﹤0.01% 1766
2024
Q2 		$14.1K Sell
4,200
-6,118
-59% -$23.8K ﹤0.01% 1752
2024
Q1 		$41.6K Sell
10,318
-1,681
-14% -$4.49K ﹤0.01% 1632
2023
Q4 		$31.8K Buy
11,999
+9,126
+318% +$20.9K ﹤0.01% 1703
2023
Q3 		$6.78K Buy
2,873
+2,365
+466% +$11K ﹤0.01% 1861
2023
Q2 		$3.2K Sell
508
-133
-21% -$814 ﹤0.01% 1954
2023
Q1 		$3.7K Sell
641
-103
-14% -$770 ﹤0.01% 1964
2022
Q4 		$7.63K Buy
+744
New +$10.1K ﹤0.01% 1896

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Federated Hermes's DSGN Position: Q4 2024 in Review

Federated Hermes sold out of Design Therapeutics (DSGN) in Q4 2024, closing a stake of 2,988 shares — an estimated $16.1K sold.

Federated Hermes first reported a position in DSGN in Q4 2022 and held it in 8 quarters. The position peaked at $41.6K in Q1 2024. 95 funds tracked by Wall St. Rank hold DSGN as of Q4 2024.

  • Federated Hermes reported no remaining Design Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 2,988 Design Therapeutics shares in Q4 2024, an estimated $16.1K.
  • Federated Hermes first reported a position in Design Therapeutics in Q4 2022 and held it in 8 quarters.
  • Federated Hermes's Design Therapeutics position peaked at $41.6K in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.